PK and PD of YG1699 in CKD Patients With Diabetes

Inclusion Criteria: 1. Ability to provide informed consent 2. Male or female patients ,age between 18 and 70 at screening 3. Meet the diagnostic criteria for diabetic nephropathy, including patients with type 1 or type 2 diabetes; 4. Fasting blood glucose \<11.1 mmol/L, stable on baseline anti-diabetic medication 5. No history of SGLT2i use within the past month 6. Hemodialysis patients must have maintenance hemodialysis for more than 3 months, with 3 sessions per week (limited to HD or HDF treatment), and spKt/V\>1.2 within 6 months 7. The patient has not used glucocorticoids, calcineurin inhibitors (cyclosporine, tacrolimus), etc. that affect blood sugar within the past month before signing the informed consent form 8. The baseline diabetes management medication regimen has been stable within the past 2 weeks. Exclusion Criteria: 1. Hypoglycemia occurs more than 2 times in one month 2. History of ketoacidosis 3. Patients who are being treated with swiram and digoxin 4. Patients with acute kidney injury (serum creatinine increased by ≥ 50% within 1 week) 5. Abnormal liver function (ALT \> 3 times the upper limit of normal value) 6. Hemoglobin \< 80g/L or \> 150g/L 7. The blood pressure of patients with recent symptomatic hypotension is lower than 90/60 mmHg 8. There is acute myocardial infarction stroke infection in the past month 9. There is systemic active infection or uncured tumor 10. The dialysis regimen of HD patients included HP treatment 11. Participating in other interventional clinical studies 12. Pregnant or lactating women 13. Other situations that the researcher thinks are not suitable for joining the study